Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries Limited reported a proposed sale of 91,345 ordinary shares through Citigroup Global Markets Inc. with an apparent aggregate value of $2,983,515.95, dated 03/04/2026. The filing lists recent dispositions by Daniell Richard of 115,468 shares on 12/09/2025 for $3,311,131.04 and 128,985 shares on 03/03/2026 for $4,173,941.70.
Teva Pharmaceutical Industries reported a Form 144 notice relating to proposed sales of its ordinary shares. The filing lists a restricted share unit award of 3,461 shares vesting on 03/03/2026. The filing also discloses insider sales by Brian Savage: 450 shares sold on 01/30/2026 and 1,000 shares sold on 12/12/2025.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed sales of ordinary shares through Citigroup Global Markets Inc., with transactions and vested compensation-related shares listed and one recent sale reported. The filing lists vested awards scheduled 03/03/2026 and a sale by Richard Francis on 02/17/2026 for 447,678 shares with amount 15324799.05.
Teva Pharmaceutical Industries disclosed a Form 144 notice reporting intended sales of ordinary shares. The filing lists restricted and performance share unit awards vesting on 03/03/2026 with quantities of 24,900, 110,668, and 30,810 shares tied to compensation awards. The broker listed is Citigroup Global Markets.
Teva Pharmaceutical Industries reports an insider Form 144 disclosing a sale of ordinary shares and upcoming compensation vesting. The filing shows 115,468 ordinary shares sold by Daniell Richard on 12/09/2025 for $3,311,131.04. The filing also lists compensation awards scheduled to vest on 03/03/2026: a Performance Share Unit award of 141,478 shares, Restricted Share Units of 24,900 shares, and Restricted Share Units (retention) of 37,350 shares.
Teva Pharmaceutical Industries Ltd executive vice president and chief financial officer Eliyahu Sharon Kalif sold 345,810 Ordinary Shares in an open-market transaction on February 26, 2026, at a weighted average price of $33.6448 per share.
After this sale, he directly held 57,478 Ordinary Shares. The shares may be represented by American Depositary Shares on a one-for-one basis, and the sale was carried out under a Rule 10b5-1 trading plan adopted on November 26, 2025.
Teva Pharmaceutical Industries Limited filed a Form 144 reporting proposed sales of ordinary shares. The filing lists proposed dispositions including 182,454 shares and 52,320 shares as examples, with the notice dated 02/26/2026. The entries are described as "shares from rollover" and "compensation" in the filing.
Teva Pharmaceutical Industries Ltd. filed an initial ownership report for interim Chief Legal Officer Brian Savage, detailing his existing equity awards and share holdings. The filing lists direct holdings of stock options, multiple tranches of restricted share units with specified vesting schedules through 2029, and ordinary shares that may be represented by American Depositary Shares. It does not record any new purchases or sales, but simply discloses current positions and how and when they vest into ordinary shares or cash.
Teva Pharmaceutical Industries’ President and CEO, Richard Francis, reported a combination of share exercises and sales. On February 15, 2026, he exercised restricted share units into ordinary shares and then sold a total of 447,778 ordinary shares at a weighted average price of $34.2241 per share, in multiple trades between $34.015 and $34.51.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 14, 2025. Footnotes state that some of the vested shares, including performance-based awards, were sold to cover tax withholding obligations. After these moves, he directly owned 605,771 Teva ordinary shares.
Teva Pharmaceutical Industries Limited filed an amendment to a Rule 144 notice that lists proposed disposition of 447,778 ordinary shares through Citigroup Global Markets. The amendment also lists 161,656 restricted share units and 620,110 performance share units, each dated 02/15/2023, with an entry date of 02/17/2026.